Comparison of six breast cancer classifiers using qPCR
暂无分享,去创建一个
Ralf Zimmer | Evi Berchtold | Gergely Csaba | Martina Vetter | Melanie Gündert | Christine Fathke | Susanne E Ulbrich | Christoph Thomssen | Eva J Kantelhardt | R. Zimmer | C. Thomssen | M. Vetter | G. Csaba | S. Ulbrich | E. Kantelhardt | E. Berchtold | Melanie Gündert | C. Fathke
[1] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Moch,et al. Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer , 2013, PloS one.
[3] A. Berjón,et al. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer , 2017, PloS one.
[4] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[5] Ramesh Ramakrishnan,et al. High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.
[6] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[7] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Mark T. W. Ebbert,et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. , 2012, The oncologist.
[9] Joel S. Parker,et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..
[10] David Venet,et al. Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..
[11] C. Perou,et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study , 2016, Breast Cancer Research and Treatment.
[12] John Quackenbush,et al. A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.
[13] R. Greil,et al. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.
[14] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[16] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[17] Zhonghu Bai,et al. Breast cancer intrinsic subtype classification, clinical use and future trends. , 2015, American journal of cancer research.
[18] Benjamin Haibe-Kains,et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues , 2009, BMC Genomics.
[19] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[20] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[21] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[23] Gianluca Bontempi,et al. Comparison of prognostic gene expression signatures for breast cancer , 2008, BMC Genomics.
[24] J. Cuzick,et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer , 2018, JAMA oncology.
[25] C. Fan,et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.
[26] J. Cuzick,et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy , 2016, Journal of the National Cancer Institute.
[27] C. Fan,et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] C. Perou,et al. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts , 2017, Clinical Cancer Research.